Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olanzapine

FDA-approved product (tablet, oral), marketed as Olanzapine, Zyprexa, Zyprexa Zydis and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Olanzapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Bipolar disorder
  • Bipolar I disorder
  • Major depressive disorder
  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diazepines, oxazepines, thiazepines and oxepines
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olanzapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olanzapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

    NCT00044187 · start 2001-04

    Registered record
    Registry ID
    NCT00044187
    Conditions
    Schizophrenia; Psychotic Disorders; Bipolar Disorder
    Interventions
    Sibutramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-04
    Completion
    2003-09
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders; Bipolar Disorder
    InterventionSibutramine
    PhasePhase 4
    Registry statusCompleted

  • Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder

    NCT00181935 · start 2001-03

    Registered record
    Registry ID
    NCT00181935
    Conditions
    Bipolar Disorder; Mania
    Interventions
    risperidone (Risperdal); olanzapine (Zyprexa)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-03
    Completion
    2004-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Mania
    Interventionrisperidone (Risperdal); olanzapine (Zyprexa)
    PhasePhase 4
    Registry statusCompleted

  • A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

    NCT00236457 · start 2000-11

    Registered record
    Registry ID
    NCT00236457
    Conditions
    Schizophrenia; Psychotic Disorders
    Interventions
    risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-11
    Completion
    2002-12
    Enrolment
    629

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders
    Interventionrisperidone
    PhasePhase 3
    Registry statusCompleted

  • Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

    NCT00183625 · start 2000-06

    Registered record
    Registry ID
    NCT00183625
    Conditions
    Schizophrenia
    Interventions
    Individual Placement and Support (Supported Employment); Social Skills Training; Olanzapine; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-06
    Completion
    2006-09
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionIndividual Placement and Support (Supported Employment); Social Skills Training; Olanzapine; Risperidone
    PhasePhase 4
    Registry statusCompleted

  • A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

    NCT00089869

    Registered record
    Registry ID
    NCT00089869
    Conditions
    Schizophrenia
    Interventions
    olanzapine; atomoxetine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionolanzapine; atomoxetine; placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted